INO Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PIRKIMAS 104746 min ago

@ $7.33

Išleistas: 14 vas. 2024 @ 20:17

Grąža: 44.20%

Ankstesnis signalas: vas. 14 - 16:30

Ankstesnis signalas: Pardavimas

Grąža: 6.23 %

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Stats
Šios dienos apimtis	193 217
Vidutinė apimtis	475 155
Rinkos kapitalizacija	273.83M
EPS	$0 ( 2024-03-06 )
Kita pelno data	( $-1.080 ) 2024-05-08
Last Dividend	$0.0690 ( 2017-09-28 )
Next Dividend	$0 ( N/A )
P/E	-1.740
ATR14	$0.0200 (0.19%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-26	Weiner David B.	Buy	972	Common Stock
2024-02-26	Weiner David B.	Buy	972	Common Stock
2024-02-26	Weiner David B.	Buy	972	Common Stock
2024-02-26	Weiner David B.	Sell	972	Restricted Stock Unit
2024-02-26	Weiner David B.	Sell	972	Restricted Stock Unit

INSIDER POWER
61.43
Last 100 transactions
Buy: 3 683 868 \| Sell: 932 723

Tūris Koreliacija

Ilgas: -0.06 (neutral)

Trumpas: -0.32 (neutral)

Signal:(42.916) Neutral

Inovio Pharmaceuticals Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
AKTX	0.966
LSXMA	0.961
LSXMK	0.961
STRO	0.95
TUEM	0.948
ASPU	0.946
OPHC	0.943
CMLS	0.942
WATT	0.942
AADI	0.941

10 Labiausiai neigiamai susiję koreliacijos
CPTA	-0.952
SGEN	-0.946
RAM	-0.936
GPACU	-0.936
NVSA	-0.936
COCO	-0.934
MLAI	-0.932
PESI	-0.928
PTOC	-0.928
FRSG	-0.927

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Inovio Pharmaceuticals Koreliacija - Valiuta/Žaliavos

0.21
( neutral )

0.26
( neutral )

0.00
( neutral )

0.29
( neutral )

0.27
( neutral )

-0.20
( neutral )

Inovio Pharmaceuticals Finansinės ataskaitos

Annual	2023
Pajamos:	$832 010
Bruto pelnas:	$-2.67M (-321.09 %)
EPS:	$-6.09

FY	2023
Pajamos:	$832 010
Bruto pelnas:	$-2.67M (-321.09 %)
EPS:	$-6.09

FY	2022
Pajamos:	$10.26M
Bruto pelnas:	$4.77M (46.44 %)
EPS:	$-14.47

FY	2021
Pajamos:	$1.77M
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-1.450

Financial Reports:

No articles found.

Inovio Pharmaceuticals Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Inovio Pharmaceuticals Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 2.18 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$0.0690	2017-06-28
Last Dividend	$0.0690	2017-09-28
Next Dividend	$0	N/A
Payout Date	2017-10-16
Next Payout Date	N/A
# dividends	4	--
Total Paid Out	$0.276	--
Avg. Dividend % Per Year	0.00%	--
Score	2.17	--
Div. Sustainability Score	2.18
Div.Growth Potential Score	0
Div. Directional Score	0.449	--

Next Divdend (Est)
(2024-06-24)

$0 Estimate 0.00 %

Dividend Stability

0.02 Very Bad

Dividend Score

2.17

Pay Frequency

Monthly

Yearly Payout

Year	Amount	Yield
2017	$0.276	3.90%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	3 430.55	1.500	10.00	10.00	[0 - 0.5]
returnOnAssetsTTM	16.50	1.200	10.00	10.00	[0 - 0.3]
returnOnEquityTTM	18.29	1.500	10.00	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	3.60	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	3.47	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	0.336	1.500	9.24	10.00	[0.2 - 2]
debtRatioTTM	0.175	-1.500	7.09	-10.00	[0 - 0.6]
interestCoverageTTM	-241.59	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	-5.80	2.00	-1.932	-3.86	[0 - 30]
freeCashFlowPerShareTTM	-5.81	2.00	-2.90	-5.81	[0 - 20]
debtEquityRatioTTM	0.257	-1.500	8.97	-10.00	[0 - 2.5]
grossProfitMarginTTM	-38.10	1.000	-10.00	-10.00	[0.2 - 0.8]
operatingProfitMarginTTM	-173.00	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-4.37	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0.00481	0.800	-3.30	-2.64	[0.5 - 2]
Total Score				2.18

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	0.0844	1.000	-0.0925	0	[1 - 100]
returnOnEquityTTM	18.29	2.50	10.00	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-5.81	2.00	-1.936	-5.81	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-5.80	2.00	-1.932	-3.86	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.0000652	1.500	-3.33	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-158.77	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-1.283

Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.